MeiraGTx Holdings (MGTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.52
- Estimate
- -$0.42
- Surprise
- +697.3%
- Revenue (period 2026-06-30)
- $321.4M
- Score at report (before → after)
- 5.3 → 5.7/10
Revenue source: xbrl.
How the report landed
MeiraGTx Holdings (MGTX) beat the -$0.42 estimate with adjusted EPS of $2.52 — a large 697.3% upside surprise. TrendMatrix's engine moved from Sell (5.3/10) to Hold at 5.7/10 after the report.
Coverage in the report window
- RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $27 — benzinga, 2026-08-14
- MeiraGTx Hldgs Q2 EPS $1.71 Beats $(0.46) Estimate, Sales $321.434M Beat $12.476M Estimate — benzinga, 2026-08-13
- MeiraGTx Hldgs Q2 Sales $321.434M Beat $12.476M Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates MGTX Buy (Wait) at 6.7/10.
1 of the last 4 quarters beat the estimate; this quarter's +697.3% surprise compares with a +33.4% four-quarter average. Next scheduled report: 2027-03-25.
What supports the rating
- High-quality business
- Attractive valuation
What argues against it
- Consecutive earnings misses (2)
- Negative momentum
- DATA_ISSUE: analyst_target_implausible (raw $27.75 vs price $8.74 — ratio 3.2×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.74
- Entry target
- $8.33
- Price target
- $10.03
- Stop
- $7.75
- Upside to target
- +14.8%
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
MGTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $897.2M
- P/E (fwd)
- -6.0
- P/E (ttm)
- 10.6
- 52-week range
- $6.62–$15.35
- Off 52-week high
- 43.1%
- RSI (14)
- 43
- Volume vs avg
- 1.09×
- Score today
- 6.7/10